These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32144533)

  • 21. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
    Papamichael D; Lopes GS; Olswold CL; Douillard JY; Adams RA; Maughan TS; Van Cutsem E; Venook AP; Lenz HJ; Heinemann V; Kaplan R; Bokemeyer C; Chibaudel B; Grothey A; Yoshino T; Zalcberg J; De Gramont A; Shi Q
    Eur J Cancer; 2022 Mar; 163():1-15. PubMed ID: 35033994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
    J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
    Gürsoy P; Çakar B; Almuradova E; Karateke M; Doğanavşargil B; Sezak M; Harman M; Karabulut B
    J Chemother; 2021 May; 33(3):180-186. PubMed ID: 33349195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study.
    Marques RP; Heudtlass P; Pais HL; Quintela A; Martins AP
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1719-1728. PubMed ID: 31037398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
    Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
    Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.
    Bai L; Wang F; Li ZZ; Ren C; Zhang DS; Zhao Q; Lu YX; Wang DS; Ju HQ; Qiu MZ; Wang ZQ; Wang FH; Xu RH
    Medicine (Baltimore); 2016 Dec; 95(51):e4531. PubMed ID: 28002313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
    Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
    J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
    Burge M; Semira C; Lee B; Lee M; Kosmider S; Wong R; Shapiro J; Ma B; Dean AP; Zimet AS; Steel SA; Lok SW; Torres J; Eastgate M; Wong HL; Gibbs P
    Clin Colorectal Cancer; 2018 Sep; 17(3):e593-e599. PubMed ID: 29958812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study.
    Liu S; Jiang C; Yang L; Huang J; Peng R; Wang X; He W; Bai L; Zhou Y; Zhang B; Xia L
    Sci Rep; 2020 Jul; 10(1):12336. PubMed ID: 32704062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
    Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
    Yoshino T; Portnoy DC; Obermannová R; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; García-Alfonso P; Cohn AL; Van Cutsem E; Yamazaki K; Lonardi S; Muro K; Kim TW; Yamaguchi K; Grothey A; O'Connor J; Taieb J; Wijayawardana SR; Hozak RR; Nasroulah F; Tabernero J
    Ann Oncol; 2019 Jan; 30(1):124-131. PubMed ID: 30339194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Zheng B; Wang X; Wei M; Wang Q; Li J; Bi L; Deng X; Wang Z
    BMC Cancer; 2019 Mar; 19(1):280. PubMed ID: 30922269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.
    Zhou YW; Long YX; Chen Y; Liu JY; Pu D; Huang JY; Bi F; Li Q; Gou HF; Qiu M
    Cancer Med; 2021 May; 10(10):3388-3402. PubMed ID: 33939281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
    Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Österlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
    Br J Cancer; 2017 May; 116(10):1271-1278. PubMed ID: 28399112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location.
    Kasper S; Foch C; Esser R; Lamy FX; Zhang A; Cheng AL; Rouyer M; Brodowicz T; Zielinski C
    Eur J Cancer; 2023 Feb; 180():85-88. PubMed ID: 36563490
    [No Abstract]   [Full Text] [Related]  

  • 40. Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy.
    Lu HJ; Lin JK; Chen WS; Jiang JK; Yang SH; Lan YT; Lin CC; Chang SC; Teng HW
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):207-15. PubMed ID: 26935130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.